ERK1 inhibitor

DRUG CLASS:

ERK1 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BRAF L597Q	Solid Tumor	BRAF L597Q	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469A	Solid Tumor	BRAF G469A	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469V	Solid Tumor	BRAF G469V	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF L485W	Solid Tumor	BRAF L485W	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF V600E	Melanoma	BRAF V600E	Melanoma	JSI-1187 Sensitive: C2 – Inclusion Criteria JSI-1187 Sensitive : C2	JSI-1187 Sensitive: C2 – Inclusion Criteria JSI-1187 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2
BRAF V600E	Melanoma	BRAF V600E	Melanoma	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2
BRAF L485W	Gallbladder Cancer	BRAF L485W	Gallbladder Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF G466A	Non Small Cell Lung Cancer	BRAF G466A	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3
KRAS G12A + BRAF D549N	Non Small Cell Lung Cancer	KRAS G12A + BRAF D549N	Non Small Cell Lung Cancer	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3
BRAF D594G	Melanoma	BRAF D594G	Melanoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF D594G	Colorectal Cancer	BRAF D594G	Colorectal Cancer	cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials cetuximab + encorafenib + BVD-523 Sensitive : C3	cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials cetuximab + encorafenib + BVD-523 Sensitive : C3
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF V600E	Pancreatic Ductal Adenocarcinoma	BRAF V600E	Pancreatic Ductal Adenocarcinoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF fusion	Glioma	BRAF fusion	Glioma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF mutation	Cholangiocarcinoma	BRAF mutation	Cholangiocarcinoma	LTT462 Sensitive: C4 – Case Studies LTT462 Sensitive : C4	LTT462 Sensitive: C4 – Case Studies LTT462 Sensitive : C4
BRAF G469A	Head and Neck Cancer	BRAF G469A	Head and Neck Cancer	BVD-523 Sensitive: C4 – Case Studies BVD-523 Sensitive : C4	BVD-523 Sensitive: C4 – Case Studies BVD-523 Sensitive : C4
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4
KRAS G13D	Non Small Cell Lung Cancer	KRAS G13D	Non Small Cell Lung Cancer	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	LY3214996 Sensitive: D – Preclinical LY3214996 Sensitive : D	LY3214996 Sensitive: D – Preclinical LY3214996 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	JSI-1187 Sensitive: D – Preclinical JSI-1187 Sensitive : D	JSI-1187 Sensitive: D – Preclinical JSI-1187 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	JSI-1187 Sensitive: D – Preclinical JSI-1187 Sensitive : D	JSI-1187 Sensitive: D – Preclinical JSI-1187 Sensitive : D
GNRHR expression	Triple Negative Breast Cancer	GNRHR expression	Triple Negative Breast Cancer	triptorelin + AEZS 136 + AEZS-134 Sensitive: D – Preclinical triptorelin + AEZS 136 + AEZS-134 Sensitive : D	triptorelin + AEZS 136 + AEZS-134 Sensitive: D – Preclinical triptorelin + AEZS 136 + AEZS-134 Sensitive : D
NRAS G13D	Mantle Cell Lymphoma	NRAS G13D	Mantle Cell Lymphoma	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D

ERK1 inhibitor

ERK1 inhibitor

Associations(46)

Associations
(46)